These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31765910)

  • 1. Piperacillin-tazobactam should be preferred to third-generation cephalosporins to treat wild-type inducible AmpC-producing Enterobacterales in critically ill patients with hospital or ventilator-acquired pneumonia.
    Carrié C; Bardonneau G; Petit L; Ouattara A; Gruson D; Pereira B; Biais M
    J Crit Care; 2020 Apr; 56():6-11. PubMed ID: 31765910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic definitive treatment in ventilator associated pneumonia caused by AmpC-producing Enterobacterales in critically ill patients: a prospective multicenter observational study.
    Petit M; Bidar F; Fosse Q; Lefevre L; Paul M; Urbina T; Masi P; Bavozet F; Lemarié J; de Montmollin E; Andriamifidy-Berti C; Dessajan J; Zuber B; Zafrani L; Peju E; Meng P; Charrier L; Le Guennec L; Simon M; Luyt CE; Haudebourg L; Geri G
    Crit Care; 2024 Feb; 28(1):40. PubMed ID: 38317262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
    Maillard A; Delory T; Bernier J; Villa A; Chaibi K; Escaut L; Contejean A; Bercot B; Robert J; El Alaoui F; Tankovic J; Poupet H; Cuzon G; Lafaurie M; Surgers L; Joseph A; Paccoud O; Molina JM; Bleibtreu A;
    Int J Antimicrob Agents; 2023 Jul; 62(1):106809. PubMed ID: 37028731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
    Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
    Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.
    McKamey L; Venugopalan V; Cherabuddi K; Borgert S; Voils S; Shah K; Klinker KP
    Int J Antimicrob Agents; 2018 Nov; 52(5):719-723. PubMed ID: 30125680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
    Taneja N; Rao P; Arora J; Dogra A
    Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combination Antibiogram Evaluation for
    Puzniak L; DePestel DD; Srinivasan A; Ye G; Murray J; Merchant S; DeRyke CA; Gupta V
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917987
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging resistance to ceftriaxone treatment owing to different ampD mutations in Enterobacter roggenkampii.
    Xie L; Xu R; Zhu D; Sun J
    Infect Genet Evol; 2022 Aug; 102():105301. PubMed ID: 35568334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
    Paterson DL; Bassetti M; Motyl M; Johnson MG; Castanheira M; Jensen EH; Huntington JA; Yu B; Wolf DJ; Bruno CJ
    J Antimicrob Chemother; 2022 Aug; 77(9):2522-2531. PubMed ID: 35781341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem.
    Holsen MR; Wardlow LC; Bazan JA; Fussner LA; Coe KE; Elefritz JL
    Int J Antimicrob Agents; 2019 Dec; 54(6):824-828. PubMed ID: 31319191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic Guidelines for Critically Ill Patients in Nigeria.
    Oladele RO; Ettu AO; Medugu N; Habib A; Egbagbe E; Osinaike T; Makanjuola OB; Ogunbosi B; Irowa OO; Ejembi J; Uwaezuoke NS; Adeleke G; Mutiu B; Ogunsola F; Rotimi V
    West Afr J Med; 2023 Sep; 40(9):962-972. PubMed ID: 37768104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative review.
    Mizrahi A; Delerue T; Morel H; Le Monnier A; Carbonnelle E; Pilmis B; Zahar JR;
    Int J Antimicrob Agents; 2020 Feb; 55(2):105834. PubMed ID: 31682902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation Rate of AmpC β-Lactamase-Producing Enterobacterales and Treatment in Clinical Practice: A Word of Caution.
    Maillard A; Dortet L; Delory T; Lafaurie M; Bleibtreu A;
    Clin Infect Dis; 2024 Jul; 79(1):52-55. PubMed ID: 38527853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are third-generation cephalosporins still an option for empirical antibiotic therapy in critically ill trauma patients with early ventilator or hospital-acquired pneumonia?
    Oddos C; Bardonneau G; Petit L; Biais M; Carrie C
    Anaesth Crit Care Pain Med; 2021 Apr; 40(2):100833. PubMed ID: 33746076
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.
    Cheng L; Nelson BC; Mehta M; Seval N; Park S; Giddins MJ; Shi Q; Whittier S; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320724
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Bacteremia Caused by
    Drozdinsky G; Neuberger A; Rakedzon S; Nelgas O; Cohen Y; Rudich N; Mushinsky L; Ben-Zvi H; Paul M; Yahav D
    Microb Drug Resist; 2021 Mar; 27(3):410-414. PubMed ID: 32808858
    [No Abstract]   [Full Text] [Related]  

  • 19. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia.
    Fowler RA; Flavin KE; Barr J; Weinacker AB; Parsonnet J; Gould MK
    Chest; 2003 Mar; 123(3):835-44. PubMed ID: 12628886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
    D'Angelo RG; Johnson JK; Bork JT; Heil EL
    Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.